HIV-1 Clade A consensus sequences, antigens, and transgenes
US8119144B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2007 |
| Grant date | Feb 21, 2012 |
| Priority date | — |
| Expiry date | Nov 8, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. In a preferred embodiment, the present invention relates to HIV-1 Clade A transgenes that are derived from such sequences, and that encode either HIV-1 Clade A Gag, Pol (RT and Int), and Nef (referred to as “GRIN”), HIV-1 Clade A Gag, RT, and Nef (referred to as (“GRN”), or HIV-1 Clade A Env. The invention also relates to vectors containing such transgenes, including in preferred embodiment, adenovirus vectors containing such transgenes. The invention also relates to immunogenic compositions comprising the HIV-1 Clade A antigens, nucleotide sequences, vectors, or transgenes of the invention, and to methods of generating an immune response against HIV in a subject by administering an effective amount of such immunogenic compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.